OMER

OmerosD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

Current thesis

The bull case is that FDA approval has already de-risked the core asset, U.S. launch is underway, EMA review could add a second leg of upside, and the Novo Nordisk deal plus debt paydown bought enough runway for Omeros to commercialize without immediate distress [#8-K-2026-03-31] [#10-K-2026-03-31].

Posture

Defensive

Lead driver

Sentiment

What changed

1 setup hits (3d) with net bullish as of 2026-06-03.

What can break

Commercial progress may be insufficient to prevent renewed equity issuance through the ATM or other financing.

Momentum

Value

Sentiment

Setup hits (3d)

1 · Net Bullish

AI TargetsBase $11.00 · Bull $18.00 · Bear $6.00

Data freshness

Prices

As of 2026-06-02

Fundamentals

As of 2026-06-01 • Vendor: Data Vendor v1

Scores

As of 2026-06-02 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-06-02

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net Bullish

Target $43.67

Why

Momentum35 · Δ7d -49.5

Value41 · Δ7d +0.1

Sentiment61 · Δ7d +10.3

So what

Weak posture (Net Bullish). Prioritize risk control and patience.

Lead driver: Sentiment · See AI snapshot

Momentum

34% active weight

Current posture

7d trendSoftening

Δ7d

-49.5

Δ21d

-59.3

Value

32% active weight

Current posture

7d trendFlat

Δ7d

+0.1

Δ21d

+0.2

Sentiment

33% active weight

Current posture

7d trendImproving

Δ7d

+10.3

Δ21d

+35.0

Why this grade

Composite grade D. Momentum 35.1 / Value 41.1 / Sentiment 61.1

Fundamentals (TTM)

As of 2026-06-01

Market Cap

$775.86M

Beta

2.46

Shares Out

70.9M

P/E (TTM) · Derived

-4.1

P/S (TTM)

P/FCF (TTM) · Derived

-6.26

Rev YoY

EPS YoY

+49.9%

Gross Margin

Op Margin

Net Debt

$315.68M

Current Ratio

0.89

As of 2026-06-02 • Updated nightlySource: Internal modelMethodology